Please select one of the topics below to view additional information.
A: A Prescription Drug Monitoring Program, (PDMP), also known as a Prescription Monitoring Program (PMP) in some states (including the Commonwealth of Virginia), is a large database that holds information detailing dispensed covered substances in that state. Most of the U.S. states and territories have their own PMP. In Virginia, the PMP contains identifying information about the prescriber, the dispenser, the patient, and the dispensed drug. The primary purpose of the PMP is to provide information about dispensed substances to prescribers and dispensers to allow them to make well-informed prescribing and dispensing decisions based on recent, accurate data. Law enforcement officers may also utilize the PMP to obtain information regarding open investigations involving drug diversion.
A: A “covered substance” is defined as follows in the PMP:
"Covered substance" means all controlled substances included in Schedules II, III, and IV; controlled substances in Schedule V for which a prescription is required; naloxone; and any drugs of concern that are required to be reported to the Prescription Monitoring Program, pursuant to this chapter.
"Covered substance" also includes cannabis oil dispensed by a pharmaceutical processor in Virginia.
Currently, Virginia does not define any drug as a “drug of concern”. Drugs of concern are often considered for scheduling by the Virginia Board of Pharmacy. Gabapentin, a Schedule V drug in the Commonwealth, had previously been considered a “drug of concern” in Virginia. The 2019 Virginia General Assembly passed HB2557, which classified gabapentin as a Schedule V controlled substance as of July 1, 2019. Beginning that date, dispensers of gabapentin were required to begin reporting gabapentin to the PMP as a Schedule V controlled substance rather than a drug of concern.
Schedule II drugs include highly addictive medications such as OxyContin and Vicodin, both potent opiates. Schedule III drugs include the lesser addictive drugs such as Tylenol with codeine, testosterone, and others. Schedule IV drugs include drugs with low abuse potential such as Tramadol and Ativan, among others. Schedule V drugs include cough medications with codeine, and Lyrica.
A: No. All dispensers in Virginia must report all dispensed prescriptions to the PMP that meet the definition of “covered substance” unless specifically exempted, regardless of the recipient of the dispensed medication.
A: Yes. If you are a prescriber or a dispenser, you may have delegates. The language authorizing the use of delegates can be found on the Virginia Legislative Automated Systems site here. Prescribers and pharmacists may have as many delegates as they need, and delegates are no longer required to hold a license, registration or certificate from one of Virginia’s health regulatory boards.
A: It depends. In order to receive “credit” for querying the PMP database, you must access your own PMP account, or have an authorized delegate access the PMP report on your behalf. If you are in an integrated solution, you must click on the PMP ribbon and view the entire report in order to get credit for querying that patient. If this access meets your needs, you may not need a delegate to query on your behalf via their own personal AWARxE login. If you have someone access the PMP on your behalf, it is very important that the individual be an authorized delegate. This is important because not only the PMP, but also other regulatory boards, have mandatory use guidelines/requirements with respect to PMP use.
A: Each Virginia PMP user must register for their own account. Usernames and passwords are not to be shared. You may instruct your delegate to register here. However, you must approve each delegate while logged into the Virginia PMP using the “Delegate Management” tab in the dropdown menu under your name in the upper right hand corner.
A: It is the responsibility of the “supervisor” to manage all of their delegates. In the AWARxE platform, log into your account and go to the “Delegate Management” tab in the dropdown menu under your name in the upper right hand corner. This will bring up a list of all your delegates. Select the delegate who has left your practice and click on the “remove” button in the lower right hand corner of the screen.
A: Please register at the following site: https://virginia.pmpaware.net/identities/new
As a delegate, you will need to have your supervisor’s email handy so that you are able to enter it as part of the registration process. Once you have submitted your registration, you will receive emails with further instructions. Because you are registering as a delegate user, your supervisor will need to approve your access through his or her AWARxE account, authorizing your use on his or her behalf.
A: The patient PMP report is limited to the last 2 years of data, including the most recent prescriptions. The purpose for the limit of two years of data is to provide you the most current, meaningful data that reflects the patient’s current risk profile. The NarxCare scores and Overdose Risk Score contained in each report are based on the last 2 years of data. For more information about the NarxCare score, click here.
A: Upon querying the PMP, the patient’s prescription history is returned in a NarxCare Report. NarxCare is a software platform which helps providers make more-informed treatment or dispensing decisions. A NarxCare report is the default presentation of this software application. The NarxCare report includes components such as scores, graphs and full prescription detail. You may click on any prescription to see more detail about that specific dispensation. A buprenorphine treatment locater is available within the NarxCare software platform to assist you in finding treatment for you patients that you suspect may have a substance use disorder (SUD).
A: Each patient report includes all medications dispensed to that individual in Schedules II-IV; all Schedule V drugs that require a prescription, all drugs of concern (currently there are no drugs of concern in Virginia), naloxone, and all products with cannabidiol oil and THC-A oils.
A: No, these facilities are not required to report their dispensing to state PDMPs in accordance with federal regulations specific to substance abuse treatment confidentiality (42 CFR Part II). For more information about the Substance Abuse Confidentiality Regulations, click here.
A: The Overdose Risk Score (ORS) can be found on each patient profile. The ORS is a relative scoring system that represents an individual’s risk of unintentional overdose death by evaluating 70 PMP variables. These scores range from 000 (read as opioid naïve) to 999. The risk of overdose death doubles every 100 points; individuals with scores of 900-999 are 300 times more likely to die than individuals with a score less than 200. For more information about the Overdose Risk Score, click here.
A: Dispensers are required to report their dispensations within 24 hours of dispensing or their next business day, whichever comes later.
A: Yes, in late December 2018 the Virginia PMP began sharing data with the Military Health Systems (MHS), also known as the Defense Health Agency (DHA). The MHS is set up just like another PMP program, so all you need to do is select MHS as one of your default PMPi states and you will see all the prescriptions for active duty military and their dependents on your PMP reports.
A: Interoperability refers to the Virginia PMP’s ability to share data with other states and other entities such as the Military Health System (MHS). This allows registered users in Virginia to include other states in their query, and the registered users in the other states to include Virginia in their query. Virginia currently shares data with the majority of states, the United States territory Puerto Rico, Washington, D.C. and Military Treatment Facilities, which includes prescriptions of all active duty military and their dependents.
A: If you are submitting a request on a patient that lives close to the border of another state, it may be in your best interest to review the prescription data collected in that state in order to determine if your patient has obtained prescriptions in that state.
A: You should first refer to your own “MyRx” report which can be found in the AWARxE platform under the “RxSearch” tab. This report shall provide a listing of every prescription that has been dispensed up to the past 10 months in reference to your DEA number. This helpful tool can provide the following:
After review of your MyRx report, if you are convinced that someone may be using your DEA number to obtain prescriptions by fraud, you may want to notify your local law enforcement agency.
A: Please update your email address under “My Profile” from the dropdown menu under your name in the upper right hand corner of your AWARxE account. It is important to keep your email address current because it serves not only as your username but as the primary means of communication for the Virginia PMP program with respect to your user account.
A: If you cannot remember your password or lost it, you may reset your password by following instructions provided by initiating the “reset password” function on the logon screen. To reset your password, you may also click here.
A: Check your “junk” or “spam” folder in your email first. If your email address has changed, or you cannot locate the reset verification password, please email the Virginia PMP staff at firstname.lastname@example.org, or call the Virginia PMP at either 804-367-4514 or 804-597-4281 for assistance.
A: There are several things to consider. If you are logged into an integrated solution, you must click on the PMP tab and view the entire report in order to get “credit” for viewing the PMP report. Simply viewing the NarxCare ribbon only will not be considered “querying the database”. If you frequently ask someone to access the PMP on your behalf, this individual must be registered as a delegate for you within the AWARxE platform, and they must also query through their personal AWARxE account.
A: There are a couple of reasons why you may not have received a prescriber report. First, if you did not supply a DEA number when registering with the PMP AWARxE platform and you never provided one after your account was established, then you will not receive a prescriber report as the prescriptions are strictly associated with your DEA number. Second, if you did not prescribe at least one opiate prescription during the 6-month period covered in the prescriber report, then you will not receive a prescriber report. Third, if you did not indicate a provider specialty in your AWARxE platform, you will not receive a prescriber report.
A: This report is intended for your own personal use. The Virginia PMP may not provide a copy of the prescriber report to anyone except the prescriber in accordance with 54.1-2523 Para C-8.
A: First, you need to complete an Account Development Form. Once this is completed, Virginia PMP staff will provide additional information to you via email concerning how to register with Clearinghouse, which is the database where you will upload your dispensing. If you have any questions during this process, please do not hesitate to contact us.
A: You must report your establishment’s dispensing within 24 hours or the next business day, whichever comes later.
A: You must report all covered substances to the Virginia PMP. Covered substances, as defined in the Code of Virginia, are as follows:
"Covered substance" means all controlled substances included in Schedules II, III, and IV; controlled substances included in Schedule V for which a prescription is required; naloxone; and all drugs of concern that are required to be reported to the Prescription Monitoring Program, pursuant to this chapter. "Covered substance" also includes cannabidiol oil or THC-A oil dispensed by a pharmaceutical processor in Virginia.
A: It is crucial that all data elements are reported to the Virginia PMP and that all elements are reported with accurate detail. Even one error or deletion of a required element can cause requesters to have difficulty obtaining complete, accurate information. For example, if the wrong date of birth is reported, it may cause this prescription to be omitted from a patient’s PMP history on the PMP report. When you receive an email that the information uploaded contained a submission error, you have five days to correct that error. This information can be found in the data reporting manual and reads as follows:
“Any data not accepted due to a substantial number of errors or omissions must be corrected and resubmitted to the vendor within five (5) days of receiving notification of the same.”
A: It is imperative when submitting animal prescriptions that you submit the owner’s name and date of birth, not the animal’s. You must also use the species code “02” indicating that the prescription belongs to an animal and not a human patient. In addition, please note that when submitting the species code “02”, you will be prompted to submit a pet name.
A: In Virginia, a drug of concern is defined as:
"Drug of concern" means any drug or substance, including any controlled substance or other drug or substance, where there has been or there is the potential for abuse and that has been identified by the Board of Pharmacy pursuant to § 54.1-3456.1.
A: No. The Virginia PMP frequently gets asked if writing a prescription is considered dispensing. If a practitioner writes a prescription and hands it to a patient or emails it to a pharmacy, this is not dispensing. There is no exchange of a controlled substance or other drug.
"Dispense" , as defined by the Board of Pharmacy, means to deliver a drug to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or compounding necessary to prepare the substance for delivery.
A: A "Recipient", as defined by the Virginia Prescription Monitoring Program, means a person who receives a covered substance from a dispenser and includes the owner of an animal patient.
A: Practitioners may obtain a certification (known as a Data Waiver) to prescribe buprenorphine or other FDA-approved medications for the treatment of opioid use disorder (OUD) outside of the Outpatient Treatment Program (OTP) setting. When prescribing these products, Data Waiver practitioners must include on the prescription their X-number and their DEA registration number. If you are using the ASAP 4.2 standard, the actual DEA number is the required data element. If you choose to use the ASAP 4.2a standard, you may submit the X-DEA number in PRE-09, along with the required DEA number in PRE02.